Interestingly, a recent study showed that TFAP2A drives melanoma metastasis by upregulating E2F pathway genes including EZH2 through inhibition of the NuRD repression complex, serving as a biomarker to predict responsiveness to EZH2 inhibitors 14. This evidence concerns the gene TFAP2A and melanoma.